299 related articles for article (PubMed ID: 20828552)
1. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
Thorsen LB; Eskildsen-Helmond Y; Zibrandtsen H; Stasch JP; Simonsen U; Laursen BE
Eur J Pharmacol; 2010 Nov; 647(1-3):147-54. PubMed ID: 20828552
[TBL] [Abstract][Full Text] [Related]
2. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats.
Deruelle P; Balasubramaniam V; Kunig AM; Seedorf GJ; Markham NE; Abman SH
Biol Neonate; 2006; 90(2):135-44. PubMed ID: 16582538
[TBL] [Abstract][Full Text] [Related]
3. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms.
Teixeira CE; Priviero FB; Todd J; Webb RC
Hypertension; 2006 Mar; 47(3):596-602. PubMed ID: 16391173
[TBL] [Abstract][Full Text] [Related]
4. Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats.
Andersen CU; Mulvany MJ; Simonsen U
Eur J Pharmacol; 2005 Mar; 510(1-2):87-96. PubMed ID: 15740728
[TBL] [Abstract][Full Text] [Related]
5. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
Lang M; Kojonazarov B; Tian X; Kalymbetov A; Weissmann N; Grimminger F; Kretschmer A; Stasch JP; Seeger W; Ghofrani HA; Schermuly RT
PLoS One; 2012; 7(8):e43433. PubMed ID: 22912874
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary pressure reduction attenuates expression of proteins identified by lung proteomic profiling in pulmonary hypertensive rats.
Østergaard L; Honoré B; Thorsen LB; Baandrup J; Eskildsen-Helmond Y; Laursen BE; Vorum H; Mulvany MJ; Simonsen U
Proteomics; 2011 Dec; 11(23):4492-502. PubMed ID: 21905223
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-4-ylamine] and YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzyl Indazole].
Teixeira CE; Priviero FB; Webb RC
J Pharmacol Exp Ther; 2006 Apr; 317(1):258-66. PubMed ID: 16352702
[TBL] [Abstract][Full Text] [Related]
8. BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump.
Bawankule DU; Sathishkumar K; Sardar KK; Chanda D; Krishna AV; Prakash VR; Mishra SK
J Pharmacol Exp Ther; 2005 Jul; 314(1):207-13. PubMed ID: 15792996
[TBL] [Abstract][Full Text] [Related]
9. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition.
Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE
J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms underlying relaxation of rabbit aorta by BAY 41-2272, a nitric oxide-independent soluble guanylate cyclase activator.
Priviero FB; Baracat JS; Teixeira CE; Claudino MA; De Nucci G; Antunes E
Clin Exp Pharmacol Physiol; 2005 Sep; 32(9):728-34. PubMed ID: 16173929
[TBL] [Abstract][Full Text] [Related]
12. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-induced pulmonary hypertension: different impact of iloprost, sildenafil, and nitric oxide.
Weissmann N; Gerigk B; Kocer O; Nollen M; Hackemack S; Ghofrani HA; Schermuly RT; Butrous G; Schulz A; Roth M; Seeger W; Grimminger F
Respir Med; 2007 Oct; 101(10):2125-32. PubMed ID: 17643279
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep.
Deruelle P; Grover TR; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2005 Nov; 289(5):L798-806. PubMed ID: 15964898
[TBL] [Abstract][Full Text] [Related]
16. Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets.
Binns-Loveman KM; Kaplowitz MR; Fike CD
Pediatr Pulmonol; 2005 Jul; 40(1):72-80. PubMed ID: 15880376
[TBL] [Abstract][Full Text] [Related]
17. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus.
Deruelle P; Grover TR; Storme L; Abman SH
Am J Physiol Lung Cell Mol Physiol; 2005 Apr; 288(4):L727-33. PubMed ID: 15608146
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats.
Priviero FB; Zemse SM; Teixeira CE; Webb RC
Am J Hypertens; 2009 May; 22(5):493-9. PubMed ID: 19247264
[TBL] [Abstract][Full Text] [Related]
19. Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching.
Chamorro V; Morales-Cano D; Milara J; Barreira B; Moreno L; Callejo M; Mondejar-Parreño G; Esquivel-Ruiz S; Cortijo J; Cogolludo Á; Barberá JA; Perez-Vizcaino F
PLoS One; 2018; 13(1):e0191239. PubMed ID: 29364918
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic Peptide activity.
Zhao L; Mason NA; Strange JW; Walker H; Wilkins MR
Circulation; 2003 Jan; 107(2):234-7. PubMed ID: 12538421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
